Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Patheon in Pact with AdventRx | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Patheon in Pact with AdventRx

Formulation, fill/finish for clinical candidate ANX-188

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

AdventRx Pharmaceuticals has entered into a multi-year agreement with Patheon under which Patheon will formulate, fill and finish ANX-188 drug product for use in clinical trials, including the Phase III study of ANX-188 that AdventRx plans to initiate this year.

ANX-188 is a rheologic, antithrombotic and cytoprotective agent that improves microvascular blood flow and has potential application in treating a wide range of diseases and conditions, such as complications arising from sickle cell disease, according to an AdventRx statement.

“This agreement is another step toward initiating the phase 3 study of ANX-188 in patients with sickle cell disease,” said Brian M. Culley, chief executive officer of AdventRx. “Patheon is a global contract manufacturer that serves more than 300 customers, including many of the world’s largest pharmaceutical and biotechnology companies. I am confident in their manufacturing expertise, experienced staff and world-class facilities and pleased to partner with them for the manufacture of ANX-188 clinical trial material.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics